Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin

Journal of Interferon and Cytokine Research

Volumn 35, Issue 1, 2015, Pages 49-54

  Esmat, Gamal ^a   El Raziky, Maissa ^a   Elsharkawy, Aisha ^a   Sabry, Dina ^a   Hassany, Mohamed ^b   Ahmed, Amal ^b   Assem, Noha ^c   El Kassas, Mohamad ^b   Doss, Wahid ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EVENING DOSAGE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER FIBROSIS; MALE; MORNING DOSAGE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ADOLESCENT; DIET SUPPLEMENTATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

HEPATITIS C VIRUS;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84921057088     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0060     Document Type: Article

References (26)

1. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. 2011. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-näve patients. World J Gastroenterol 17(47):5184-5190.
2. Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, Al-Ahdal MN, Mayet I, Khan MQ, Kessie G. 2004. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 24(6):568-574.
3. Amr N, Hamid A, Sheta M, Elsedfy H. 2012. Vitamin D status in healthy Egyptian adolescent girls. Georgian Med News (210):65-71.
4. Bedossa P, Poynard T. 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24(2):289-293.
5. Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, Bignulin S, Cmet S, Fontanini E, Falleti E, Martinella R, Pirisi M, Toniutto P. 2011. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transplant Int 24(1):43-50.
6. Cholongitas E, Theocharidou E, Goulis J, Tsochatzis E, Akriviadis E, Burroughs K. 2012. Review article: the extraskeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther 35(6):634-646.
7. El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A. 2005. Response of hepatitis C genotype-4 näve patients to 24 weeks of Peginterferon-alpha2b/ribavirin or induction-dose interferonalpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 100(11):2447-2452.
8. Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME. 2012. The future for the treatment of genotype 4 chronic hepatitis C. Liver Int 32 (Suppl. 1):146-150.
9. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncąles FL Jr, Haüssinger D, Diago M, Carosi G, Dhumeaux D, Crax A, Chaneac M, Reddy KR. 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43(3):425-433.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. American Association for the Study of Liver Diseases AASLD PRACTICE GUIDELINES Diagnosis, Management, and Treatment of Hepatitis C: An Update. Hepatology 49(4):1335-1374.
11. Gutierrez JA, Parikh N, Branch AD. 2011. Classical and emerging roles of vitamin D in hepatitis C virus infection. Semin Liver Dis 31(4):387-398.
12. Hamza RT, Awwad KS, Ali MK, Hamed AI. 2011. Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity. Med Sci Monitor 17(12):CR711-CR718.
13. Heijboer AC, Blankenstein MA, Kema IP, Buijs MM. 2012. Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration. Clin Chem 58(3): 543-548.
14. Hollis BW. 2008. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr 88(2): 507S-510S.
15. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. 2005. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 54(6):858-866.
16. Kitson MT, Dore GJ, George J, Button P, McCaughan GW, Crawford DH, Sievert W, Weltman MD, Cheng WS, Roberts SK. 2013. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol 58(3):467-472.
17. Kitson MT, Roberts SK. 2012. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 57(4):897-909.
18. Ladero JM, Torrejón MJ, Sánchez-Pobre P, Suárez A, Cuenca F, de la Orden V, Devesa MJ, Rodrigo M, Estrada V, López-Alonso G, Agúndez JA. 2013. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. Ann Hepatol 12(2): 199-204.
19. Llovet JM, Burroughs A, Bruix J. 2003. Hepatocellular carcinoma. Lancet 362(9399):1907-1917.
20. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. 2002. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123(4):1061-1069.
21. Meguid NA, Hashish AF, Anwar M, Sidhom G. 2010. Reduced serum levels of 25-hydroxy and 1,25-dihydroxy vitamin D in Egyptian children with autism. J Altern Complement Med 16(6):641-645.
22. Nimer A, Mouch A. 2012. Vitamin D improves viral response in hepatitis C genotype 2-3 näve patients. World J Gastroenterol 18(8):800-805.
23. Petta S, Cammà C, Scazzone C, Tripodo C, Di Marco V, Bono A, Cabibi D, Licata G, Porcasi R, Marchesini G, Crax A. 2010. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 51(4):1158-1167.
24. Sarrazin C, Shiffman ML, Hadziyannis SJ, Lin A, Colucci G, Ishida H, Zeuzem S. 2010. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 52(6):832-838.
25. Terrier B, Carrat F, Geri G, Pol S, Piroth L, Halfon P, Poynard T, Souberbielle JC, Cacoub P. 2011. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 55(4):756-761.
26. Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N. 2007. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother 51(6):2016-2027.